An Investigator Sponsored Phase I Study of the Safety, Tolerability and Pharmacodynamics of Escalating Doses of Combination Treatment of AZD5363 + Olaparib + Durvalumab (MEDI4736) in Patients With Advanced or Metastatic Solid Tumor Malignancies
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Capivasertib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms MEDIPAC
Most Recent Events
- 13 Sep 2022 Results (n=39) reporting efficacy data from both dose escalation and expansion cohorts presented at the 47th European Society for Medical Oncology Congress
- 19 Dec 2018 New trial record